Arie Perry, MD
Specialties: Brain and spinal cord tumors
Dr. Perry is a neuropathologist who specializes in the diagnosis of brain and spinal cord tumors. In addition to over 25 years of experience as a pathologist, Dr. Perry also leads several translational research projects focusing on the development of new diagnostic and prognostic markers for gliomas, meningiomas, and primitive pediatric malignancies.
Dr. Perry’s specific research interests include the improvement of tumor classification and grading schemes, as well as the identification of molecular and genetic markers associated with tumorigenesis, malignant progression, and/or biologic behavior. His hope is that identifying new markers will improve patient management and lead to the development of novel therapeutic approaches.
1986: BS, The University of Texas at Austin
1990: MD, UT Southwestern Medical Center
1994: Residency, Anatomic and Clinical Pathology, UT Southwestern Medical Center
1998: Fellowship; Surgical Pathology, Neuropathology, and Research; Mayo Clinic
1997-1998: Instructor, Pathology, Mayo Clinic School of Medicine
1998-2003: Assistant Professor, Pathology, Washington University School of Medicine
2003-2008: Associate Professor, Pathology, Washington University School of Medicine
2008-2010: Professor, Pathology, Washington University School of Medicine
2009-2010: Professor, Neurosurgery, Washington University School of Medicine
2010-Present: Professor, Pathology, UCSF
2010-Present: Professor, Neurosurgery, UCSF
2010-Present, Director of Neuropathology, UCSF
2025: Appointed as US and Canadian Academy of Pathology (USCAP) Secretary
2023-2025: Co-Chair for cIMPACT-NOW Update 8: Clarifications on WHO grading and molecular risk parameters for meningiomas
2023-Present: Member of the American Board of Pathology Test Development and Advisory Committee (ABP TDAC) for Neuropathology
2022: Listed in top 1% of the 2022 Highly Cited Researchers in the Clarivate/Web of Science for the category of Neuroscience and Behavior
2022: Dorothy Russell Lectureship, British Neuropathological Society (BNS)
2022: Harvey Goldman Master Teaching Award, US and Canadian Academy of Pathology (USCAP)
2021-2025: Assigned as North American Chief Editor for 10th Edition of Greenfield’s Neuropathology (main 2 volume reference textbook utilized internationally)
2020-2021: Served as an Expert Editor for the World Health Organization (WHO) 5th edition of the Central Nervous System Tumours scheme
2018: Elected as a Board of Directors Member for the United States and Canadian Academy of Pathology
2018: Society for Neuro-Oncology in Latin America International Imaging and Pathology Recognition Award
2017: Member of International Collaboration on Cancer Reporting for the development of a reporting protocol for tumours of the central nervous system
2016: Member of cIMPACT‑NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
2016: Appointed to the Editorial Advisory Board for the American Registry of Pathology Publications
2015: Appointed President of American Association of Neuropathologists for 2016-2017
2015: Appointed President Elect of American Association of Neuropathologists for 2015-2016
2014: Appointed as Senior Reviewer for WHO 4th edition brain tumor classification scheme update
2014: Appointed Vice President of International Society of Neuropathology for 2015-2018
2012-2015: Served as North American Chief Editor for 9th Edition of Greenfield’s Neuropathology
2013: Nominated for MS1 Essential Core Teaching Award, UCSF
Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis type 1 (NF1)
Lucas CG, Gross AM, Romo CG, Dehner CA, Lazar AJ, Miettinen M, Pekmezci M, Quezado M, Rodriguez FJ, Stemmer-Rachamimov A, Viskochil D, Perry A; Symposium on Atypical Neurofibroma: State of the Science Members.
Neuro Oncol. 2025 Mar 7;27(3):616-624.
cIMPACT-NOW Update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas
Sahm F, Aldape KD, Brastianos PK, Brat DJ, Dahiya S, von Deimling A, Giannini C, Gilbert MR, Louis DN, Raleigh DR, Reifenberger G, Santagata S, Sarkar C, Zadeh G, Wesseling P, Perry A.
Neuro Oncol. 2025 Feb 10;27(2):319-330.
High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience
Terry M, Nguyen MP, Tang V, Guney E, Bharani KL, Dahiya S, Choutka O, Borys E, Reis G, Blevins L, Aghi MK, Kunwar S, DeGroot J, Raleigh DR, Pekmezci M, Bollen AW, Cha S, Joseph NM, Perry A.
Endocr Pathol. 2024 Dec;35(4):338-348.